Evidence map›Paper›PMID 35711449›Full record

ArticleFrontiers in immunology2022

Evaluation of Antibody-Dependent Fc-Mediated Viral Entry, as Compared With Neutralization, in SARS-CoV-2 Infection.

Lindsay Wieczorek, Michelle Zemil, Mélanie Merbah, Vincent Dussupt, Erin Kavusak, Sebastian Molnar, Jonah Heller, Bradley Beckman, Suzanne Wollen-Roberts, Kristina K Peachman and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Lindsay WieczorekU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, United States.
Michelle ZemilU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, United States.
Mélanie MerbahU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, United States.
Vincent DussuptU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, United States.
Erin KavusakU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, United States.
Sebastian MolnarU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, United States.
Jonah HellerU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, United States.
Bradley BeckmanU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, United States.
Suzanne Wollen-RobertsU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, United States.
Kristina K PeachmanDiagnostics and Countermeasures Branch, Walter Reed Army Institute of Research, Silver Spring, MD, United States.
Janice M DardenHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, United States.
Shelly KrebsU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, United States.
Morgane RollandU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, United States.
Sheila A PeelDiagnostics and Countermeasures Branch, Walter Reed Army Institute of Research, Silver Spring, MD, United States.
Victoria R PolonisU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, United States.
Walter Reed Army Institute of Research · USHenry M. Jackson Foundation · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fc-mediated virus entry has been observed for many viruses, but the characterization of this activity in convalescent plasma against SARS-CoV-2 Variants of Concern (VOC) is undefined. In this study, we evaluated Fc-mediated viral entry (FVE) on FcγRIIa-expressing HEK293 cells in the presence of SARS-CoV-2 convalescent plasma and compared it with SARS-CoV-2 pseudovirus neutralization using ACE2-expressing HEK293 cells. The plasma were collected early in the pandemic from 39 individuals. We observed both neutralization and FVE against the infecting Washington SARS-CoV-2 strain for 31% of plasmas, neutralization, but not FVE for 61% of plasmas, and no neutralization or FVE for 8% of plasmas. Neutralization titer correlated significantly with the plasma dilution at which maximum FVE was observed, indicating Fc-mediated uptake peaked as neutralization potency waned. While total Spike-specific plasma IgG levels were similar between plasma that mediated FVE and those that did not, Spike-specific plasma IgM levels were significantly higher in plasma that did not mediate FVE. Plasma neutralization titers against the Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1) and Delta (B.1.617.2) VOC were significantly lower than titers against the Washington strain, while plasma FVE activity against the VOC was either higher or similar. This is the first report to demonstrate a functional shift in convalescent plasma antibodies from neutralizing and FVE-mediating against the earlier Washington strain, to an activity mediating only FVE and no neutralization activity against the emerging VOC, specifically the Beta (B.1.351) and Gamma (P.1) VOC. It will be important to determine the

Indexed as

COVID-19SARS-CoV-2COVID-19 SerotherapyHEK293 CellsHumansImmunization, PassiveImmunoglobulin Fc FragmentsSpike Glycoprotein, CoronavirusVirus InternalizationImmunoglobulin Fc FragmentsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2antibody dependent enhancementcoronavirus – COVID-19Fc-mediated virus entryneutralizationpseudovirusSARS-CoV-2spike (S) proteinvariant of concern

Identifiers

PMID35711449
PMCPMC9193970
OpenAlexW4281753400

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.